Annovis Bio, Inc. (ANVS) — 8-K Filings

8-K Filings (38)

• Annovis Bio 8-K: Officer/Director Changes, Comp Arrangements — Mar 25, 2026
  Annovis Bio, Inc. filed an 8-K on March 25, 2026, reporting events from March 23, 2026, under Item 5.02, which typically covers changes in directors or officers
• Annovis Bio Files 8-K on Financials — Nov 13, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on November 13, 2025, reporting events as of November 12, 2025. The filing pertains to Results of Operations and Financial Condit
• Annovis Bio Files 8-K — Oct 28, 2025 Risk: medium
  Annovis Bio, Inc. filed an 8-K on October 28, 2025, reporting on events that occurred on October 26, 2025. The filing indicates the entry into a material defini
• Annovis Bio, Inc. Files 8-K for Material Definitive Agreement — Oct 14, 2025 Risk: medium
  On October 10, 2025, Annovis Bio, Inc. entered into a material definitive agreement. The company, previously known as QR Pharma, Inc., is incorporated in Delawa
• Annovis Bio Appoints New CMO, Elects Director — Sep 29, 2025 Risk: medium
  Annovis Bio, Inc. announced on September 25, 2025, the departure of Dr. Michael J. McVicar as Chief Medical Officer. The company also elected Dr. Maria L. Macce
• Annovis Bio: CEO Shifts to CSO, New CMO Appointed — Aug 15, 2025 Risk: medium
  Annovis Bio, Inc. announced on August 11, 2025, changes in its board of directors and executive compensation. Dr. Maria Maccecchini, the CEO, will transition to
• Annovis Bio Files 8-K on Operations — Aug 12, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• Annovis Bio Files 8-K on Shareholder Votes & Financials — Jun 23, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders and financial statements as of June 17, 2025. The
• Annovis Bio Files Current Report — Jun 20, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on June 20, 2025, reporting an event on June 19, 2025. The filing is a current report pursuant to Section 13 or 15(d) of the Secu
• Annovis Bio Files 8-K on Financials and Personnel — May 13, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 13, 2025, reporting on results of operations and financial condition, director/officer changes, and financial statements.
• Annovis Bio 8-K: Delisting Notice, Director Changes, Officer Appointments — Mar 27, 2025 Risk: high
  Annovis Bio, Inc. filed an 8-K on March 27, 2025, reporting several key events. These include a notice of potential delisting or failure to meet continued listi
• Annovis Bio Files 8-K on Financials — Mar 21, 2025 Risk: low
  Annovis Bio, Inc. filed an 8-K on March 21, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements
• Annovis Bio Enters Material Definitive Agreement — Feb 5, 2025 Risk: medium
  Annovis Bio, Inc. announced on February 3, 2025, that it entered into a material definitive agreement. The filing also includes other events and financial state
• Annovis Bio Enters Material Definitive Agreement — Dec 11, 2024 Risk: medium
  Annovis Bio, Inc. announced on December 11, 2024, that it has entered into a material definitive agreement. The filing does not provide specific details about t
• Annovis Bio CEO Change and Director Departure — Dec 9, 2024 Risk: medium
  Annovis Bio, Inc. announced on December 4, 2024, the appointment of Dr. Maria L. Maccecchini as Chief Executive Officer and a member of the Board of Directors.
• Annovis Bio Files 8-K on Financials — Nov 12, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• Annovis Bio Files 8-K — Oct 15, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The company, formerly known as QR Pharma, Inc., is incorpor
• Annovis Bio Files 8-K for Financials and Exhibits — Sep 30, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on September 30, 2024, reporting on financial statements and exhibits. The company, previously known as QR Pharma, Inc., is incor
• Annovis Bio Files 8-K on Financials — Aug 15, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• Annovis Bio Files 8-K — Aug 6, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on August 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• Annovis Bio Files 8-K, Updates Corporate Info — Jul 16, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on July 16, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's
• Annovis Bio Files 8-K — Jul 10, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on July 10, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
• Annovis Bio Files 8-K — Jul 2, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on July 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• Annovis Bio Files 8-K on Security Holder Vote — Jun 13, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific
• Annovis Bio Prices $10M Registered Direct Offering — Jun 11, 2024 Risk: medium
  Annovis Bio, Inc. announced on June 11, 2024, that it has entered into a securities purchase agreement to sell approximately $10.0 million of its common stock i
• Annovis Bio Partners with Pfizer for Alzheimer's Drug Trial — Jun 5, 2024 Risk: medium
  Annovis Bio, Inc. announced on June 5, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate Annovis's lead drug candidate,
• Annovis Bio Files 8-K — May 21, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 21, 2024, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or ma
• Annovis Bio Files 8-K on Financials — May 13, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exh
• Annovis Bio Files 8-K for Financial Statements — May 9, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 9, 2024, reporting on its financial statements and exhibits. The company, previously known as QR Pharma, Inc., is incorpor
• Annovis Bio Files 8-K — May 6, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 6, 2024, reporting on its financial statements and exhibits. The company, previously known as QR Pharma, Inc., is incorpor
• Annovis Bio Files 8-K — May 2, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on May 2, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or detail
• Annovis Bio Files 8-K: Board and Compensation Updates — May 1, 2024 Risk: medium
  Annovis Bio, Inc. filed an 8-K on May 1, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes fin
• Annovis Bio Enters Material Definitive Agreement — Apr 26, 2024 Risk: medium
  Annovis Bio, Inc. announced on April 25, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about the agre
• Annovis Bio Files 8-K on Financials — Apr 3, 2024 Risk: low
  Annovis Bio, Inc. filed an 8-K on April 3, 2024, reporting on its results of operations and financial condition as of April 2, 2024. The filing details financia
• Annovis Bio Partners with Pfizer for Alzheimer's Trial — Mar 22, 2024 Risk: medium
  Annovis Bio, Inc. announced on March 22, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the combination of Annovis'
• Annovis Bio Enters Material Definitive Agreement — Mar 21, 2024 Risk: medium
  Annovis Bio, Inc. announced on March 21, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific details of the ag
• Annovis Bio Partners with Pfizer for Alzheimer's Trial — Mar 20, 2024 Risk: medium
  Annovis Bio, Inc. announced on March 19, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the combination of Annovis'
• Annovis Bio Files 8-K for Material Agreement — Mar 15, 2024 Risk: medium
  Annovis Bio, Inc. filed an 8-K on March 15, 2024, reporting the entry into a material definitive agreement and the filing of financial statements and exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX